Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327

Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound

Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327

Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce weighs in on Q1 2024 as cash increases 100%

Recce weighs in on Q1 2024 as cash increases 100%

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals up 6% on new antibiotic production milestone